Biomarkers of Premature Biological Aging in Hodgkin Lymphoma Survivors: Advanced Glycation End Products, Oxidative Stress, Inflammation and Cellular Senescence
Antioxidants · 10.11.2026 · 15 (11) · 1457
DOI: 10.3390/antiox15111457 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antioxidants, online erschienen am 10.11.2026. Verfasst von Eleonora Aimaretti und 17 weiteren Autor:innen. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CRT Foundation, University of Turin.
Abstract (Originalsprache)
Childhood, adolescent, and young adult cancer survivors (CAYACS) are at increased risk of late morbidity, potentially reflecting premature biological aging. Cellular senescence, oxidative stress, and chronic inflammation may contribute via interconnected pathways, including signaling mediated by advanced glycation end products (AGEs) and their receptor, RAGE. This study investigated biomarkers related to these pathways in CAYACS-treated Hodgkin lymphoma (HL) patients, comparing their biological profile with that of age-matched (Controls 1) and older (aged 50–65) healthy controls (Controls 2). HL survivors exhibited accumulation of AGEs, higher expression of their receptor RAGE and lower circulating levels of soluble RAGE compared to age-matched Controls 1. A similar profile of AGE-RAGE signaling was observed in Controls 2. HL survivors and Controls 2 showed an altered oxidative status. Moreover, HL survivors reported higher plasma levels of IL-6 than age-matched controls. Furthermore, HL survivors and Controls 2 showed alterations in autophagy and mitophagy. Finally, CAYACS had higher plasma MMP9 levels and higher p16 mRNA levels than age-matched Controls 1. Data show that CAYACS exhibit a biological profile consistent with premature cellular senescence, with several features resembling those observed in older healthy individuals. Alterations in AGE-RAGE signaling, oxidative stress-related pathways, and chronic inflammation may lead to the onset of this phenotype. Further longitudinal studies are needed to clarify the potential role of these biological alterations in the development of long-term treatment-related complications.
Förderung
- CRT Foundation
- University of Turin
Zitieren
APA
Aimaretti, E., Rubeo, C., Levis, M., Botto, B., Cavallo, F., Presti, M., Pettineo, E., Alves, G. F., Bello, F. D., Godono, A., Freilone, R., Bruno, B., Ricardi, U., Arvat, E., Pizzimenti, S., Aragno, M., Collino, M., & Felicetti, F. C. (2026). Biomarkers of Premature Biological Aging in Hodgkin Lymphoma Survivors: Advanced Glycation End Products, Oxidative Stress, Inflammation and Cellular Senescence. Antioxidants, 15(11), 1457. https://doi.org/10.3390/antiox15111457
Vancouver
Aimaretti E, Rubeo C, Levis M, Botto B, Cavallo F, Presti M, et al. Biomarkers of Premature Biological Aging in Hodgkin Lymphoma Survivors: Advanced Glycation End Products, Oxidative Stress, Inflammation and Cellular Senescence. Antioxidants. 2026;15(11):1457. doi:10.3390/antiox15111457
BibTeX
@article{Aimaretti2026,
author = {Aimaretti, Eleonora and Rubeo, Chiara and Levis, Mario and Botto, Barbara and Cavallo, Federica and Presti, Michela and Pettineo, Elisa and Alves, Gustavo Ferreira and Bello, Federica Dal and Godono, Alessandro and Freilone, Roberto and Bruno, Benedetto and Ricardi, Umberto and Arvat, Emanuela and Pizzimenti, Stefania and Aragno, Manuela and Collino, Massimo and Felicetti, Francesco Carlo},
title = {Biomarkers of Premature Biological Aging in Hodgkin Lymphoma Survivors: Advanced Glycation End Products, Oxidative Stress, Inflammation and Cellular Senescence},
journal = {Antioxidants},
year = {2026},
volume = {15},
number = {11},
pages = {1457},
doi = {10.3390/antiox15111457}
}
EUVIMED